Oncotype Dx Breast Cancer Assay in Older Patients: A Real Life Cohort
This observational study highlights that the Oncotype DX test supports therapeutic de-escalation in patients with RS ≤ 25 and serves as a prognostic marker. Oncogeriatric evaluations are essential to guide adjuvant treatments in older breast cancer patients prior to using genomic signatures.
Authors
- Jean‐Pierre Lotz (ORCID: https://orcid.org/0000-0003-1771-7051)
- Coralie Prebet
- Marc‐Antoine Benderra (ORCID: https://orcid.org/0000-0001-9338-0345)
- Anne Sabaila
- Mathieu Jamelot (ORCID: https://orcid.org/0000-0002-3719-3833)
- Marjolaine Le Gac
- Joseph Gligorov (ORCID: https://orcid.org/0000-0002-9900-6386)
- Djamel Ghebriou (ORCID: https://orcid.org/0000-0003-2263-7304)
- David Buob (ORCID: https://orcid.org/0000-0002-6847-6377)
- Mariana Nedelcu
- Lauren Seknazi
- Clément Grosnon (ORCID: https://orcid.org/0009-0001-0234-4152)
Institutions
- Sorbonne Université (FR)
- Hôpital Tenon (FR)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2025-11-01
- DOI
- https://doi.org/10.1002/cam4.71386
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00